A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes

Naofumi Asano, Juntaro Matsuzaki, Makiko Ichikawa, Junpei Kawauchi, Satoko Takizawa, Yoshiaki Aoki, Hiromi Sakamoto, Akihiko Yoshida, Eisuke Kobayashi, Yoshikazu Tanzawa, Robert Nakayama, Hideo Morioka, Morio Matsumoto, Masaya Nakamura, Tadashi Kondo, Ken Kato, Naoto Tsuchiya, Akira Kawai and Takahiro Ochiya ()
Additional contact information
Naofumi Asano: National Cancer Center Research Institute
Juntaro Matsuzaki: National Cancer Center Research Institute
Makiko Ichikawa: Toray Industries
Junpei Kawauchi: Toray Industries
Satoko Takizawa: Toray Industries
Yoshiaki Aoki: Dynacom Co., Ltd.
Hiromi Sakamoto: National Cancer Center Research Institute
Akihiko Yoshida: National Cancer Center Hospital
Eisuke Kobayashi: National Cancer Center Hospital
Yoshikazu Tanzawa: National Cancer Center Hospital
Robert Nakayama: Keio University School of Medicine
Hideo Morioka: Keio University School of Medicine
Morio Matsumoto: Keio University School of Medicine
Masaya Nakamura: Keio University School of Medicine
Tadashi Kondo: National Cancer Center Research Institute
Ken Kato: National Cancer Center Hospital
Naoto Tsuchiya: National Cancer Center Research Institute
Akira Kawai: National Cancer Center Hospital
Takahiro Ochiya: National Cancer Center Research Institute

Nature Communications, 2019, vol. 10, issue 1, 1-10

Abstract: Abstract Due to their rarity and diversity, sarcomas are difficult to diagnose. Consequently, there is an urgent demand for a novel diagnostic test for these cancers. In this study, we investigated serum miRNA profiles from 1002 patients with bone and soft tissue tumors representing more than 43 histological subtypes, including sarcomas, intermediate tumors, and benign tumors, to determine whether serum miRNA profiles could be used to specifically detect sarcomas. Circulating serum miRNA profiles in sarcoma patients were clearly distinct from those in patients with other types of tumors. Using the serum levels of seven miRNAs, we developed a molecular detector, Index VI, that could distinguish sarcoma patients from benign and healthy controls with remarkably high sensitivity (90%) and specificity (95%), regardless of histological subtype. Index VI provides an approach to the early and precise detection of sarcomas, potentially leading to curative treatment and longer survival.

Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-019-09143-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09143-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-09143-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().